You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. A dual histone deacetylase and glycogen synthase kinase 3 beta inhibitor for treating pancreatic adenocarcinoma

    SBC: Avenzoar Pharmaceuticals, Inc.            Topic: 102

    ABSTRACT Pancreatic cancer is a disease with no effective treatmentIt s low five year survival rateestimated at betweenandranks it the fourth highest of cancer related of death in the U Sdespite being the twelfth most common type of cancerEach year in the U Sthere are nearlynew cases and more thandeaths caused by the diseaseBypancreatic cancer is expected to be the second most common cancer relate ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Advanced Morphing Moulage for Medical Training (AMM-MT)

    SBC: Vcom3D, Inc.            Topic: DHA17A002

    For this Phase I SBIR proposal, Vcom3D proposes to design advanced medical moulage that accurately simulates the progression of an injury or pathology by morphing through a series of clinical states to enable learners to confirm the progression of the wound and to determine whether iatrogenic errors or pathologies occurred duing treatment. The physical morphing moulage may be applied to medical m ...

    STTR Phase I 2017 Department of DefenseDefense Health Program
  3. AHTP-comet: development of an automated, high throughput comet assay system

    SBC: Engineering Resources Group, Inc            Topic: NIEHS

    PROJECT SUMMARY Genomic instabilityinduced by DNA damageand partly mitigated by DNA repair and antioxidantsplays a critical role in the pathogenesis of many major human diseasessuch as neurodegenerationcancer and cardiovascular diseasetogether with agingThere is a critical need for automated assays that can perform these assessmentsand bring them into greater routine usewhich will help advance our ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. A microfluidic device for blood analysis in neonates

    SBC: Sersense Inc            Topic: NICHD

    ABSTRACT Premature infants are frequently at risk of infectionjaundice and hypoglycemiaconditions monitored by analysis of blood for c reactive proteinCRPbilirubin and glucose respectivelyTypicallymL of blood is drawn each time an infant is tested with multiple blood draws happening over the course of daysGiven that total blood volume of in premature infants ismLup toof blood volume may be lost du ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. An Advanced Lung Organomimetic to Reproduce Human Airway Pathophysiology

    SBC: Pneumax, LLC            Topic: 113

    PROJECT SUMMARYThree of top five causes of death in humans globally are lung relatedchronic obstructive pulmonary diseaseCOPDlower respiratory infections and lung cancers collectively account for over eight million deaths annuallyCurrentlyin preclinical settingstatic cell cultures and animal models are the most widely used systems for mechanistic and translational studiesHowevercritical limitation ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. An epitope focused nanoparticle vaccine for MRSA and biodefense

    SBC: VLP BIOTECH, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and of increasing concern in the community where it results in severe skin infections pneumonia bacterial endocarditis and sepsis A significant proportion of these infections are the result of methici ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. An integrative multi phenotype pipeline for drug evaluation pharmacogenomics and attribute prediction

    SBC: PHENVOGEN LLC            Topic: 300

    PROJECT SUMMARY The process of drug discovery is costly and many promising compounds fail during clinical trials By then expenses upward of $ million dollars per failed drug may have incurred and these financial risks hamper research efforts and ultimately reduce the availability of treatment options In this research proposal we are using systematic approaches to map the relationships be ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. A novel anti gonorrhea immunotherapeutic

    SBC: Planet Biotechnology Incorporated            Topic: NIAID

    Antimicrobial resistance is a major public health problem worldwide Neisseria gonorrhoeae Ng the causative agent of the sexually transmitted infection gonorrhea has become multidrug resistant and has achieved superbug status Novel therapeutics against Ng are urgently needed Complement C is a key arm of innate immune defenses A mechanism used by several pathogens including Ng to esca ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. A Novel Two-in-One Approach to Administer Surfactant and Provide Airway Support to VLBW Infants

    SBC: BB MEDICAL SURGICAL, INC.            Topic: NICHD

    PROJECT SUMMARYABSTRACT Every yearvery low birth weightVLBWandltginfants are born in the U SThe use of surfactant dramatically decreases morbidity and mortality due to respiratory distress syndromeRDSin VLBW infantsCurrent standards for surfactant administration require the infant to be intubatedso that surfactant can be delivered to the trachea and lungsIntubating a VLBW infant is challenging and ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. A Portable Device for Accurate Mouse Tail Vein Injection

    SBC: Technology Commercialization Partners LLC            Topic: OD

    PROJECT SUMMARYABSTRACT To datethe standard method to access a mouse tail vein is manual injectionbut its yield rate is poor in generalThis leads to multiple needle insertions associated with tissue damage and painBesidesfailure in tail vein injection leads to data lossand thereby more animals will be required to compensate itFinallythe dose variation induced by unreliable injection increases erro ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government